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Abstract
Alzheimer’s Disease (AD) ravages the cognitive ability of more than 5 million Americans
and creates an enormous strain on the health care system. This paper proposes a machine
learning predictive model for AD development without medical imaging and with fewer
clinical visits and tests, in hopes of earlier and cheaper diagnoses. That earlier diagnoses
could be critical in the effectiveness of any drug or medical treatment to cure this disease.
Our model is trained and validated using demographic, biomarker and cognitive test
data from two prominent research studies: Alzheimer’s Disease Neuroimaging Initiative
(ADNI) and Australian Imaging, Biomarker & Lifestyle Flagship Study of Aging (AIBL).
We systematically explore different machine learning models, pre-processing methods
and feature selection techniques. The most performant model demonstrates greater than
90% accuracy and recall in predicting AD, and the results generalize across sub-studies
of ADNI and to the independent AIBL study. We also demonstrate that these results
are robust to reducing the number of clinical visits or tests per visit. Using a meta-
classification algorithm and longitudinal data analysis we are able to produce a ”lean”
diagnostic protocol with only 3 tests and 4 clinical visits that can predict Alzheimer’s
development with 87% accuracy and 79% recall. This novel work can be adapted into
a practical early diagnostic tool for predicting the development of Alzheimer’s that
maximizes accuracy while minimizing the number of necessary diagnostic tests and
clinical visits.
Author summary
The main goal of this paper is to propose a machine learning solution for the problem
of predicting the risk of developing Alzheimer’s Disease (AD). This is achieved by
systematically analyzing medical records from two of the longest longitudinal studies of
AD, ADNI and AIBL. We analyze different machine learning algorithms as well as feature
selection methods and preprocessing techniques. Our proposed solution encompasses a
diagnostic protocol for early testing of AD that has high accuracy and recall while also
minimizing the number of diagnostic tests the patient is subjected to and eliminating
the need for costly imaging data. This renders our solution both accurate as well as
practical for an early detection program of AD.
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1 Introduction
Alzheimer’s Disease (AD) is the most common cause of dementia, a group of brain
disorders that cause the loss of intellectual and social skills. AD manifests as a progressive,
degenerative disorder that attacks the brain’s nerve cells, or neurons, resulting in loss of
memory, thinking and language skills, as well as behavioral changes [1]. Currently AD is
an irreversible process with no cure. The personal, social and economic impact of AD is
profound: In the United States, more than 5 million people aged 65 or over are suffering
from Alzheimer’s disease and the estimated national cost of patient care for Alzheimer’s
and other dementias was $236 billion in 2016 [2]. Further, AD is the sixth leading cause
of death in the US (third for older people) [3].
Although Alzheimer’s was first identified more than a century ago, effective treatments
have proved elusive. Drug and non-drug treatments can help alleviate some cognitive
and behavioral symptoms of AD, but there is still no cure. Researchers continue to work
on developing treatments that can reverse disease progression and improve the quality
of life for people with Alzheimer’s. One of the critical challenges for dealing with AD
is the lack of understanding about the neurodegenerative process associated with this
disease. There are currently two widely-believed, competing hypotheses:
1) The amyloid hypothesis: One prime suspect for AD is a microscopic brain protein
fragment called beta-amyloid. This protein is a sticky compound that accumulates
in the brain, disrupting communication between brain cells and eventually killing
them. Some researchers believe that flaws in the processes governing production,
accumulation or disposal of beta-amyloid are the primary cause of Alzheimer’s [4].
2) The tau hypothesis: The accumulation of the tau protein is thought to be a major
player in the development of Alzheimer’s disease. In particular, the tau hypothesis
asserts that the formation of neurofibrillary tangles (insoluble twisted fibers that
are formed inside the cells) causes the development of AD [5].
Given the huge social and economic impact of any potential treatment for AD, several
companies are actively researching this field. Recent research has created optimism that
a treatment for AD is close to fruition [6]. Regardless of the treatment, one critical
aspect for the practical deployment of any potential AD drug is the ability for this drug
to be used widely and preventively [9]. Thus, this work aims to provides a model, using
two well-known studies of Alzheimer’s disease (ADNI and AIBL), that is both suitable
for early detection and practically applicable in clinical settings. To achieve this aim, we
strategically evaluate our model’s performance with the smallest (and least expensive)
feature subsets so that our model can be used for early screening, before any symptoms
appear. Our model utilizes features including demographics, biomarkers, and cognitive
tests. Due to the prohibitive expense of medical imaging data (e.g., MRI and PET
scans) as an early detection test, we remove medical imaging as a possible feature. Our
machine learning approach uses metrics derived from longitudinal data analysis, and our
analysis evaluates optimal feature selection techniques, data imputation methods, and
classification algorithms. Ultimately our goal is to provide a cost-effective pre-screening
test battery for Alzheimer’s disease.
1.1 Literature Review
We explored existing literature regarding Alzheimer’s prediction as well as longitudinal
data handling. Prediction of Alzheimer’s is a popular area of research with researchers
applying a plethora of supervised learning techniques to the problem. We also found
existing literature that worked with the same main data set that we use in our study,
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ADNI. In general we find that Support Vector Machines are the most popular machine
learning technique applied to this problem [11] [12]. However, recently Neural networks
have gained popularity [13], and novel approaches have been attempted, including using
Natural Language Processing to find linguistic deficits [12]. The biggest difference be-
tween most studies predicting Alzheimer’s and our work lies in our exclusion of medical
imaging as a feature for the model. Our goal was to produce a model that could aid in
early detection, and the cost of medical imaging is a deterrent for people who are unsure
about getting tested for the disease. Therefore, we excluded medical imaging (PET
and MRI) from our analysis. The literature that uses medical imaging has produced
accuracies of 80% [14] and recalls of 85% [15] in predicting conversion to Alzheimer’s.
The few models that do not include medical imaging data, instead using cognitive tests
and demographics, have accuracies of less than 85% [16]. Ultimately, this is a ripe
general area for research, but there are a dearth of studies considering prediction without
the use of medical data.
We also conducted a literature review for longitudinal data analysis, which is very
relevant for the type of data typically associated with AD clinical studies. In our case, the
longitudinal nature of the AD data results from the observation of subjects (patients) over
time during sequential clinical visits. The difficulty in dealing with this data stems from
the inconsistent number of observations across patients and the potentially correlated
data within patients. The literature for longitudinal data analysis is extensive [17] [18].
Methods based on summary metrics or statistics [19] have been broadly used, where
temporal measurements are summarized into key statistical descriptors (e.g., mean, mode,
area-under the curve, etc). Another common solution to handle longitudinal data is to
fit this data using some type of regression model. Regression models permit inference
regarding the dynamic response over time and how this evolution varies with patient
characteristics such as treatment assignment or other demographic factors. However,
standard regression methods assume that all observations are independent, and this
may produce invalid standard errors if the assumptions are not valid. For this reason,
advanced regression methods have been proposed to overcome some of these limitations
such as Random-Coefficient Models [20] and General Regression Methods [21]. Some of
these models are very flexible in allowing for imbalanced data, missing values, differing
number of time points from subject to subject, and unequal spacing of time point intervals
within and across subjects. In addition, recent work has been done applying machine
learning techniques such as Neural Networks [22] and Support Vector Classifiers [23]
to longitudinal data. For the work presented here, summary metrics have been shown
to provide great results in generating features for predictive modeling, with the added
benefit of generating more parsimonious models.
2 Materials and methods
2.1 Data
For this study we have utilized two existing repositories for AD studies: ADNI [24] and
AIBL [26]:
The ADNI (Alzheimer’s Disease Neuroimaging Initiative) dataset is an ongoing,
longitudinal multi-study that has been carried out since 2004. It has acquired data and
specimens from 1,700 participants at 60 clinical sites around Canada and the United
States. The study enrolls selected populations for future treatment, and the subjects
include AD patients, mild cognitive impairment subjects, and an elderly control. The
successes of the ADNI database includes developing standardized methods, improving
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trial efficiency, and creating an infrastructure for sharing raw and processed data without
embargo. The initiative is supported by $67 million in private and public sector donations.
The initial phase of the study is known as ADNI1. In 2009, the second phase, ADNIGO,
was started containing 200 participants with Early Mild Cognitive Impairment. In
2011, the third phase, ADNI2, began with 150 participants with Late Mild Cognitive
Impairment.
The AIBL (Australian Imaging, Biomarker & Lifestyle Flagship Study of Aging)
dataset contains data from a 4.5 year longitudinal study of cognition which started in
2006. It is a large scale cohort study containing 1,112 participants and conducted at
two centers, Perth and Melbourne, in Australia. The study focuses on early detection,
specifically in terms of lifestyle interventions. The AIBL data contains 211 AD patients,
133 MCI patients, and 768 healthy volunteers and follows the ADNI1 protocols for data
collection. The available data includes clinical and cognitive data, image data (extracted
from MRI and PET data), biomarker data including blood, genotype, and ApoE, and
dietary and lifestyle data. These latter assessments examine participant’s diet, exercise
patterns, body composition, and sleep habits. [26].
More detailed clinical description of the ADNI and AIBL cohorts have been previously
published in [25] and [26] respectively. It is worth noticing that AIBL and ADNI
have many of the same goals and are designed to identify the biomarkers, cognitive
characteristics, and health and lifestyle factors that impact AD.
For this study we used 94 predictors that were reported in the ADNIMERGE table
(a special dataset that merges key ADNI tables). These predictors provided specific
information about patient demographics, genetics, blood biomarkers and cognitive tests
from participants in different longitudinal multi-center studies.
Model Procedure
We experiment with multiple different pre-processing techniques, feature selection meth-
ods, and machine learning models. The specific options we experimented with are
delineated below.
• Data-Preprocesing : Our data pre-processing includes generation of the labels,
conversion of categorical variables, longitudinal data handling and imputation.
First, we generated labels for our classification problem by merging features across
the different data files in the ADNI dataset. We then excluded 14 subjects who
were diagnosed as AD but then were diagnosed as either cognitively normal (CN)
or mild cognitive impairment (MCI) in future years (there is currently no way to
reverse AD so this indicates a mistake in the data).
We next one-hot encoded all categorical variables and performed feature engineer-
ing. For all longitudinal features, we computed a series of summary metrics (mean,
standard deviation, absolute changes and time intervals) for each patient that
captured their temporal evolution along multiple clinical visits. Finally, we split
the data into a training and test set and performed imputation. We investigated
imputation by mean or mode (mean for numerical columns and mode for categorical
columns), and k-Nearest Neighbors imputation.
• Feature Reduction and Selection: Our data is high-dimensional, so we experimented
with two different feature reduction techniques: Singular Value Decomposition
and Affinity Propagation. Singular Value Decomposition, or SVD [27] operates by
combining information from several (likely) correlated vectors, and forming basis
vectors which explain most of the variance in the data and are guaranteed to be
orthogonal in higher dimensional space. SVD and PCA (Principal Component
June 17, 2020 4/14
Analysis, a very popular dimensionality reduction technique) are closely related.
On the other hand Affinity Propagation, or AP [28] is a relatively new clustering
algorithm based on the concept of ”message passing” between data points. Once
we obtain clusters of features then we can compute the so-called exemplars (fea-
tures that are good representatives of themselves and some other features). This
approach provides an elegant feature selection technique. Notice that AP does not
require the number of clusters to be determined or estimated before running the
algorithm (and this is in contrast to other clustering techniques such as k-means),
although a user of this technique must sill define some hyperparameters (e.g.,
preferences) that affect the resulting number of clusters.
• Supervised Learning : The supervised learning module performs five-fold cross
validation and grid search over the hyperparameters and model selection specified
in the pipeline. The models implemented in our pipeline were Random Forest,
Logistic Regression, k-Nearest Neighbors, Support Vector Machines (SVM), Multi-
layer Perceptron (MLP), AdaBoost, Linear SVM, Gradient Boosting, and Decision
Trees. More details for these methods can easily be found in machine learning
literature [29] [30]. Using the parameters that maximize recall on the validation
set, the model predicts and outputs the labels for the test set.
• Model Evaluation: Finally, the predictions of our model are evaluated against
the true labels using the following metrics: confusion matrix, accuracy, recall,
precision, f1 score, and ROC curve. In this work, we focus on optimizing model
accuracy (percentage of patients correctly labeled by our model) and recall (per-
centage of patients who develop AD that are correctly identified) [32]. In medical
settings, like predicting AD development, it is often crucial to minimize false
negatives, and therefore we try to optimize the recall of our models. However,
our pipeline automatically computes the full suite of metrics for potential use in
further exploration.
We evaluated every possible combination of model parameters (imputation, feature
selection and model type) in order to quantify their predictive power. For each possible
model, we assess the performance on fifty different random training and test set splits
where the ratio of training to test data is 2:1. For these experiments, we use the entire
ADNI dataset. We carry out five-fold cross-validation to pick the top four model/
hyperparameter combinations that maximize recall on the validation set, and record
metrics across one hundred random splits of the train and test set to prove consistency
of our results.
2.2 Evaluation of Model’s Promise for Early Detection of AD
We also investigated whether our model can generalize, how much longitudinal data we
need before we can make accurate predictions, and whether we can produce a ”lean”
model that minimizes time/money cost while maintaining high accuracy and recall.
2.2.1 Model Generalization
We also conducted a series of analyses in order to determine whether our model can
generalize across different study protocols. We first explore the robustness of our top two
models on the different sub-studies of ADNI. We train and test the model separately on
ADNI1, ADNI2, and ADNIGO and record our four performance metrics. Next, we train
a model on the ADNI1 dataset and then test separately on the ADNI2 dataset and the
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ADNIGO dataset. Likewise, we try all other pairs of sub-studies for the training and test
sets. We also analyzed our model’s performance on the AIBL dataset. Note that AIBL
represents a completely different repository of patients to ADNI (i.e., different patients
following different protocols), which gives us an excellent opportunity to validate our
data-driven solutions for AD prediction. For this particular study we considered the
handful of features that are common to both AIBL and ADNI repositories: Age, Gender,
APOE4 (a genetic test) and MMSE (a cognitive test).
Longitudinal Data Analysis
As described earlier, one of our goals is to propose a practical data-driven solution for
AD predictions that can be used in clinical settings. For this purpose, it is important to
understand how the longitudinal dimension of the data (e.g., number of visits) affect the
performance of our predictions. To evaluate this, we trained our model assuming that
the full history of the patients in the training set was available. Then we tried to predict
the label for the test set patients with restricted information from a limited number of
visits. This analysis aims to evaluate the number of medical visits necessary for obtaining
a given performance in predicting AD. The relationship between the number of visits
and total time of study (from baseline to last visit) was also considered in this analysis.
Cost Analysis
To evaluate whether we can limit the cost for a patient while still providing an accurate
prediction, we take two approaches. First, we research the time that patients spend on
each test and then plot the features of our model against the time needed to obtain
those features, with the features ordered by feature importance (as determined by the
Random Forest algorithm).
Secondly, we utilize a meta-classification algorithm to produce models that have high
accuracies and recalls while minimizing the testing time for the patient. We follow the
approach of [33] and build a meta-model, a Decision Tree, that balances accuracy of
prediction with time cost (for the patient). First we generate the meta-classification
dataset. We group our features into twelve different categories: demographics (e.g.
age, gender, education), APOE4 genetic marker data, information about the number of
years since the baseline diagnosis, and nine different cognitive test features. We first
produce the power set of the original twelve features. Then we take all sets in the power
set that have size 1, 2 or 3 (a total of 298 sets to be considered). For each of these
sets of features, we train a Random Forest model on the given features. The labels
predicted by each of these 298 models become a feature in our meta-classification dataset.
The meta-classification model is a decision tree which splits based on the algorithm
designed by [33]. Instead of choosing a node to split on based on information gain, we
choose the node, Mi, that has the maximal
Information Gain(Mi)
Expected Cost(Mi)
where Information Gain
is Shannon Information Gain and Expected Cost is defined as Expected Cost(Mi) =
PL(Mi)Cost(Mi)+(1−PL(Mi))[
∑
v∈CMi
∑m
j=i+1 PL(Mj |Mi = v)Cost(Mj |Mi = v)] [33]
. Ultimately, this splitting criterion balances information gain with the cost of using the
given model. We use this algorithm to create a decision tree that balances feature cost
and information gain.
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8Model Comparison
ROC	Curves- 50	train/test	splits
Fig 1. ROC Curve for Random Forest with mean/mode imputation (mean for
numerical features and mode for categorical), no feature selection, and 1,000 trees. Small
labels over the curve show the different thresholds used to make the class predictions.
Results
Comparison of Models
For all the model parameter combinations, we determine that the best two models
(with the highest recall on the validation set) are: 1. Random Forest with mean/mode
imputation, no feature selection, and 1,000 trees and 2. Random Forest with k-Nearest
Neighbors imputation, no feature selection, and 1,200 trees. Table 1 shows the perfor-
mance in terms of accuracy, recall, precision and F1 score. These scores are averaged
across one hundred different random training and test set splits. Both our top models
glean an average accuracy greater than 92% and an average recall greater than 91%,
with the Model 1 having higher accuracy and Model 2 having higher recall. We produce
an ROC curve for Model 1 which demonstrates the strong model performance (Figure
1).
Further we identify the features that are most important for Model 1 (Figure 2).
As shown, the top five most important features are related to longitudinal metrics for
CDRSB, FAQ, ADAS11, ADAS13, and MMSE, which are all cognitive tests.
Table 1. Comparison of Metrics for Top 2 Models
Accuracy Recall Precision F1 Score
Model 1 92.51 91.76 89.33 90.48
Model 2 92.44 92.04 88.84 90.35
Model Performance on ADNI sub-studies
We test Model 1 and Model 2 when trained/tested on ADNI1, ADNI2, and ADNIGO
separately. The models based on ADNI1 data and ADNI2 data have similar accuracies
and recalls compared to the models trained on the full ADNI dataset. The models
trained on solely ADNIGO data has a high accuracy, but low recall with high result
variance. This is most likely a consequence of the different demographics of the sub-
studies: only 10% of the ADNIGO patients developed AD versus 30% and 50% patients
in ADNI2 and ADNI1, respectively. Further, ADNIGO only has 129 patients versus
789 in ADNI2 and 819 in ADNI1, making the training sample much smaller for ADNIGO.
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Fig 2. Feature Importances for Top 25 Features in Model 1
Finally, for each pair of sub-studies, we train on one study and test on the other to
determine whether our model generalizes across the different sub-studies. The different
sub-studies have slightly different protocols and patient demographics, so we explore
whether the results of one study can accurately predict the AD status of the patients
in another. We find greater than 90% recall when training on ADNI1 or ADNI2 and
testing on the other two studies. However, when the model is trained on the ADNIGO
dataset, the recall when testing on ADNI1 or ANDI2 plummets to approximately 14%.
We expect this is due to the small number of Alzheimer’s patients in the ADNIGO
dataset and the small sample size. Ultimately, this analysis shows that our best models
generalize well on different training and testing subsets of ADNI data, as long as there
is a sufficiently large training set size with a moderate amount of Alzheimer’s patients.
Validation of Model with AIBL Data
One of the stretch goals for this study was the evaluation of our predictive models with
patients that are part of a completely different repository such as AIBL. To this end, we
considered a total of 861 patients from the AIBL database (note: for the ADNI repository
we considered 1737 patients). Since AIBL uses slightly different protocols, a direct merge
of both databases was not possible. Thus, we focused our analysis on a limited number
of features that are consistently available in both ADNI and AIBL patients. Although
small in size, this set of features includes the demographics of the patients (age and
gender), their genetic characterization (APOE4) and their responses to a well-known
cognitive test (MMSE). An important consideration is that the distribution of these
features across the ADNI and AIBL populations is not exactly the same. The ADNI
dataset has more men than women, and AIBL patients tend to be older than ADNI
patients. The distributions of MMSE scores and APOE4 results look approximately the
same between the two studies, after taking into account the difference in samples sizes.
We conducted two different studies involving the AIBL data:
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• AIBL Test 1: We merged all patients (i.e., ADNI and AIBL) into a single set and
then split them (randomly) into training and test sets (without consideration of
what repository patients belong to). From here we ran 100 different simulations
using Model 1 (Random Forest with mean/mode imputation, no feature selection,
and 1,000 trees).
• AIBL Test 2: In this study we trained a model using all ADNI patients and then
we assigned all AIBL patients to the test set. We ran 100 different simulations
using Model 1.
Results for accuracy, recall, prediction and f1 score for these two tests using AIBL
data are summarized in Table 2. These results demonstrate that when merging ADNI and
AIBL patients into one single study our predictive model still yields high accuracy (90.0%)
and recall (85.0%). When training on ADNI patients and testing on AIBL patients, we
also obtain high accuracy; however, we observe a lower recall and precision. We expect
that these results could be improved with domain adaptation and the introduction of
more common features to both AIBL and ADNI.
Table 2. Metrics for models that consider AIBL data
Accuracy Recall Precision F1 Score
AIBL Test 1 90% 85% 82% 83%
AIBL Test 2 93% 80% 69% 74%
Longitudinal Data Analysis
Next, we investigated how the predictive power of our best models are affected by the
number of visits available for each patient. Number of visits is strongly correlated with
the length of time a patient has been in the study. We also investigate the distribution
of the maximum number of years that ADNI patients have been studied (see Figure 3).
This figure shows that approximately 80% of the ADNI patients have endured 4 years or
less of study under this protocol, while only 20% of the patients have undergone more
than 4 years of study.
Using Model 1 (as used in Table 1) we ran 100 samples for random splits of the ADNI
patients into training and validation sets. For the training set we assumed that the full
history of visits was known (history is known). However, for patients in the test set, we
fixed the maximum number of visits that could be used in computing the longitudinal
features of the patients. Results, which are shown in Table 3, clearly indicate that the
performance of the predictive model improves as the number of visits for test patients
increase. This trend is expected, as additional visits provide more valuable information
about the patient evolution. The main contribution of Table 3 is the quantification
of this trend. We see, for example, that achieving 89% accuracy requires at least 6
clinical visits for an average patient (meaning approximately 2.5 to 4.5 years of study). A
guarantee of 85% recall on the prediction would require around 16 visits for the average
patients (roughly equivalent to 8-10 years of study). Hence this table potentially provides
a valuable tool for doctors and patients to understand the number of visits required in
order to obtain predictions for AD with a satisfying confidence level.
Cost Analysis and Meta-Classification
When we plot the time needed to obtain the features for each successive model versus
the accuracy of these models, we see that after approximately 217 minutes of testing,
the accuracy of the models plateau (Figure 4). Note that when a longitudinal metric, for
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Table 3. Longitudinal Analysis: prediction metrics vs. number of visits
# Visits # Years since baseline [range] # Test Patients Accuracy Recall Precision F1 Score
1 [0.3 - 1] 574 79 65 79 70
2 [0.5 - 2] 550 86 75 88 81
4 [1.5 - 3] 494 87 78 88 83
6 [2.5 - 4.5] 371 89 81 86 83
8 [4 - 6] 221 89 83 84 84
12 [6 - 8] 81 89 80 89 84
16 [8 - 10] 45 90 85 89 87
Fig 3. Histogram for maximum number of years ADNI patients have been studied
example mean CDRSB, is added to the model already containing another longitudinal
metric for the same feature, e.g. standard deviation of CDRSB, no extra testing time is
required to include this feature. Therefore, the x-axis contains duplicated values.
An example of a meta-classification Decision Tree is included in Figure 5, with the
accuracy and recall scores averaged over fifty random training and test set splits to
ensure robustness of results. The accuracy, recall and time needed to perform the tests
are provided for each level in the tree. Note that accuracy increases by level, but that
recall peaks at Level 1, most likely because this is a more generalizable model. Note that
even with the the Level 1 tree, trained on just three cognitive tests, CDRSB, ADAS13,
and MOCA, which only take a combined 1 hour and 27 minutes, our model is able to
predict with better than 90% accuracy and recall. The CDRSB (Clinical Dementia
Rating Box Score) takes 30 minutes approximately and is scored based on the results
from an interview with the patient and the patient’s caregiver. ADAS11 is one of the
Fig 4. Accuracy with Successive Features Added to Model versus Time of Medical
Tests
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26
91.87%	Accuracy
90.32%	Recall
1	hour,	27	minutes
91.89%	Accuracy
89.67%	Recall
3	hours,	27	minutes
93.52%	Accuracy
90.08%	Recall
3	hours,	57	minutes
CDRSB,	ADAS13,	MOCA
Demographics,	
ADAS11,	MMSE
Demographics,	
MMSE,	RAVLT
Demographics,
MMSE
Demographics,
ADAS13,	ECogPt
CDRSB,	FAQ,	
ECogSP FAQ,	ECogSP
Fig 5. Example of Decision Tree produced by Meta-Classification
most popular cognitive tests for AD consisting of a 45 minute written test containing 11
questions. Finally MOCA (Montreal Cognitive Assessment) is a brief written test that
takes approximately 12 minutes to complete. Note that CDRSB and ADAS11 rank in
the top five most important features in Figure 2. The inclusion of MOCA is most likely
a result of its low time cost.
While we currently only consider the cost of features in terms of the patient’s time,
this model could easily incorporate the monetary cost of these tests as well. These results
show that this type of meta-classification model can perform very well, suggesting its
possible implementation as a data-driven diagnostic tool. Using this model, the patient
and doctor can weigh whether the added specificity and sensitivity warrant the extra
time and cost of the medical test.
We also considered the possibility of combining longitudinal analysis with meta-
classification. For this analysis, we took the features in the Level 1 model (CDRSB,
ADAS13 and MOCA) and ran an analysis similar to the one presented in the Longitudinal
Analysis section. Results are presented in Table 4. Once again, this table quantifies the
performance of the predictive models (in this case using only the 3 features of Level 1
tree) for different numbers of clinical visits. Compared to Table 3, the number of visits
required to achieve 89% accuracy using only these three features would be larger (16 vs
6). Nevertheless, these results indicate that good performance for AD prediction can
still be achieved using a limited number of visits and a reduced set of features.
Table 4. Longitudinal Analysis: prediction metrics vs. number of visits using Level 1
tree features from meta-classification analysis
# Visits # Years since baseline [range] # Test Patients Accuracy Recall Precision F1 Score
1 [0.3 - 1] 574 78 64 77 69
2 [0.5 - 2] 550 85 77 84 81
4 [1.5 - 3] 494 87 79 86 82
6 [2.5 - 4.5] 371 87 81 79 81
8 [4 - 6] 221 87 84 80 82
12 [6 - 8] 81 87 80 87 82
16 [8 - 10] 45 89 87 87 86
Discussion
Our work shows that it is possible to build a data-driven model that can confidently
predict the risk of developing Alzheimer’s in the future with a level of accuracy and recall
that are above 90%. The necessary data for such a prediction is patient demographic
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information, a genetic test (APOE4 genotyping) and a battery of cognitive tests. We
demonstrated that imaging data (MRI and PET scans), which are more costly in terms of
time and money, are not necessary for highly accurate predictions. We also demonstrated
how well our model generalizes by evaluating the model performance for different ADNI
sub-studies (testing one against the others and quantifying model performance) and
against a cohort of patients that belong to a completely different repository (AIBL). In
all cases, our predictive models show very robust performance.
We carefully quantified the impact that the number of clinical visits of data available
for a patient has on the predictive performance of our model. We also implemented
a meta-classification technique to identify the combination of features that provide
the optimal balance between model prediction and feature cost. In each case we have
identified models that can still provide a high level of accuracy and recall. We believe
our work provides the right framework for a practical deployment of an AD predictive
tool in clinical settings. As an example, we have proposed a diagnostic protocol with
only 3 tests and 4 clinical visits that can predict AD with 87% accuracy and 79% recall.
Ultimately our model framework could be used by physicians and patients together
to determine appropriate plans for diagnosis and monitoring of the risk of developing AD.
Any potential model to be deployed in real world settings will have to perform well
relative to a clinician. Based on the literature, physicians can diagnose Alzheimer’s
with 87% accuracy and 91% recall [34]. Our best models produce equivalent or better
predictions relative to physicians for the harder problem of predicting future development
of AD. Going forward, a parallel study of model prediction versus physician prediction
would be necessary to validate the models and gain doctor’s trust in this method. A
limitation to this approach is due to our training labels being provided by doctors. Those
”true” labels carry some level of uncertainty as AD is a difficult disease to diagnose in
vivo. Our predictive models are ultimately only as good as the training data used to
build them. Finally, it is important to recognize that this work has focused on proposing
models that offer high predictive performance, with no consideration for interpretation
of these models. Expected FDA new regulations for CDS (Clinical Decision Support)
software could incentivize developing models.
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